Synopsis
Synopsis
0
KDMF
0
VMF
0
Canada
0
South Africa
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers


1. Apokinon
2. Apomorphin Teclapharm
3. Apomorphin-teclapharm
4. Apomorphine
5. Apomorphine Chloride
6. Apomorphine Hydrochloride Anhydrous
7. Apomorphine Hydrochloride, Anhydrous
8. Apomorphine Hydrochloride, Hemihydrate
9. Britaject
1. 314-19-2
2. Apomorphine Hcl
3. Apomorphine Chloride
4. (r)-(-)-apomorphine Hydrochloride
5. Apokinon
6. Apomorphinium Chloride
7. Apomorphine Hydrochloride Anhydrous
8. Uprima
9. N-methylnorapomorphine Hydrochloride
10. Nsc-11442
11. 9k13md7a0d
12. Apomorphine Sl
13. Taluvian
14. Ixense
15. 41372-20-7
16. Apomorphine Hydrochloride Hemihydrate
17. Apomorphinum Muriaticum
18. Apomorphin Hydrochlorid
19. (-)-apomorphine Hydrochloride
20. Britaject
21. Pomorphini Hydrochloridum
22. Apomorphinum Hydrochloricum
23. Apomorphine Hydrochloride Hydrate
24. Kw-6500
25. (-)-apomorphinium Hydrochloride
26. Nsc-755875
27. Einecs 206-243-0
28. Nsc 11442
29. Unii-9k13md7a0d
30. Apomorphine-hcl
31. Apomorphinehydrochloride
32. 6a-beta-aporphine-10,11-diol, Hydrochloride
33. (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Hydrochloride
34. Prestwick_28
35. 6abeta-noraporphine-10,11-diol, 6-methyl-, Hydrochloride
36. 6a-beta-noraporphine-10,11-diol, 6-methyl-, Hydrochloride
37. R-(-)-apomorphine Hcl
38. 6abeta-aporphine-10,11-diol, Hydrochloride
39. 5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)chinolin-10,11-diol Hydrochlorid
40. Schembl8524
41. Chembl1616
42. (r)-(-)-apomorphine Hcl
43. Dtxsid5040598
44. Apomorphine Hydrochloride (r,-)
45. Apomorphine, Hydrochloride
46. R-(-)-apomorphine Hydrochloride
47. (-)-apomorphine (hydrochloride)
48. (r)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol Hydrochloride
49. Anhydrous Apomorphine Hydrochloride
50. Nsc11442
51. Apomorphine Hydrochloride [mi]
52. 6a.beta.-aporphine-10, Hydrochloride
53. Akos024456928
54. H72a207
55. 4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, Hydrochloride, (6ar)-
56. 4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, Hydrochloride, (r)-
57. B6936
58. Sr-01000597777
59. J-018414
60. Sr-01000597777-1
61. 6a.beta.-aporphine-10,11-diol Hydrochloride
62. 6a.beta.-noraporphine-10, 6-methyl-, Hydrochloride
63. Q27272658
64. Wln: T C6666 1a Q Kn & Tt & J Dq Eq K1 & Gh
65. (r)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo[de,g]quinoline-10,11-diol Hydrochloride
66. 4h-dibenzo[de,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, Hydrochloride, (r)-
67. (6ar)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(de,g)quinoline-10,11-diol Hydrochloride
68. 4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, Hydrochloride (1:1), (6ar)-
1. Apomorphine Hydrochloride Hydrate
| Molecular Weight | 303.8 g/mol |
|---|---|
| Molecular Formula | C17H18ClNO2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 303.1026065 g/mol |
| Monoisotopic Mass | 303.1026065 g/mol |
| Topological Polar Surface Area | 43.7 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 374 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Uprima to be effective, sexual stimulation is required.
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Taluvian to be effective, sexual stimulation is required.
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Ixense to be effective, sexual stimulation is required.
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Emetics
Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla. (See all compounds classified as Emetics.)
G04BE
G04BE
G04BE
Details:
Aposan (Apomorphine HCl) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of parkinson disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Aposan
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2026
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rusan Introduces APOSAN 3ml Pen for Motor Fluctuations
Details : Aposan (Apomorphine HCl) is a small molecule drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of parkinson disease.
Product Name : Aposan
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2026
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SER-252 (Apomorphine) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of parkinson disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: SER-252
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
Details : SER-252 (Apomorphine) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of parkinson disease.
Product Name : SER-252
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Apomorphine HCl, a controlled substance targeting dopamine receptors, shows promise in treating Parkinson's Disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Kynmobi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apomorphine HCl, a controlled substance targeting dopamine receptors, shows promise in treating Parkinson's Disease.
Product Name : Kynmobi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
NT-301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): NT-301,Apomorphine Hydrochloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NT-301,Apomorphine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial of Intranasal Delivery of NT-301
Details : NT-301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Aporon
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Orion Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 25, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Orion And Criceto Sign License Deal for APORON Spray in Parkinson’s Disease
Details : Under the licensing agreement, Orion will hold the exclusive rights of the Aporon(apomorphine HCl), which is being evaluated for the treatment of OFF episodes in patients with Parkinson’s disease.
Product Name : Aporon
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 25, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Onapgo (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, & is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Onapgo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Supernus' Drug-Device Combination for Parkinson's Disease
Details : Onapgo (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, & is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Product Name : Onapgo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, and is investigated for motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Supernus Provides Regulatory Update for SPN-830
Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which acts as dopamine D2 receptor agonist, and is investigated for motor fluctuations (OFF episodes) in Parkinson’s disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 02, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Details : SPN-830 (apomorphine) is a novel and less invasive therapy, which is acts as dopamine D2 receptor agonist, which is investigated for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Apomorphine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Lead Product(s): Apomorphine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Peachtree BioResearch Solutions | DSG | ISS, Inc.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apomorphine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Peachtree BioResearch Solutions | DSG | ISS, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apomorphine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
Reply
01 Apr 2026
Reply
10 Mar 2026
Reply
12 Jul 2025
Reply
01 Jan 2025
Reply
03 Jul 2021
Reply
22 Apr 2021
Reply
30 Dec 2019
Reply
12 Feb 2019
Reply
15 Aug 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
31
PharmaCompass offers a list of Apomorphine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Apomorphine Hydrochloride manufacturer or Apomorphine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Apomorphine Hydrochloride manufacturer or Apomorphine Hydrochloride supplier.
A Apomorphine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Apomorphine Hydrochloride, including repackagers and relabelers. The FDA regulates Apomorphine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Apomorphine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Apomorphine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Apomorphine Hydrochloride supplier is an individual or a company that provides Apomorphine Hydrochloride active pharmaceutical ingredient (API) or Apomorphine Hydrochloride finished formulations upon request. The Apomorphine Hydrochloride suppliers may include Apomorphine Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Apomorphine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Apomorphine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Apomorphine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Apomorphine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Apomorphine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Apomorphine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Apomorphine Hydrochloride USDMF includes data on Apomorphine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Apomorphine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Apomorphine Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Apomorphine Hydrochloride Drug Master File in Japan (Apomorphine Hydrochloride JDMF) empowers Apomorphine Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Apomorphine Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Apomorphine Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Apomorphine Hydrochloride suppliers with JDMF on PharmaCompass.
A Apomorphine Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Apomorphine Hydrochloride Certificate of Suitability (COS). The purpose of a Apomorphine Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Apomorphine Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Apomorphine Hydrochloride to their clients by showing that a Apomorphine Hydrochloride CEP has been issued for it. The manufacturer submits a Apomorphine Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Apomorphine Hydrochloride CEP holder for the record. Additionally, the data presented in the Apomorphine Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Apomorphine Hydrochloride DMF.
A Apomorphine Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Apomorphine Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Apomorphine Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Apomorphine Hydrochloride written confirmation (Apomorphine Hydrochloride WC) is an official document issued by a regulatory agency to a Apomorphine Hydrochloride manufacturer, verifying that the manufacturing facility of a Apomorphine Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Apomorphine Hydrochloride APIs or Apomorphine Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Apomorphine Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Apomorphine Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Apomorphine Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Apomorphine Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Apomorphine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Apomorphine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Apomorphine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Apomorphine Hydrochloride suppliers with NDC on PharmaCompass.
Apomorphine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Apomorphine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Apomorphine Hydrochloride GMP manufacturer or Apomorphine Hydrochloride GMP API supplier for your needs.
A Apomorphine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Apomorphine Hydrochloride's compliance with Apomorphine Hydrochloride specifications and serves as a tool for batch-level quality control.
Apomorphine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Apomorphine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Apomorphine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Apomorphine Hydrochloride EP), Apomorphine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Apomorphine Hydrochloride USP).